Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 331

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

Morgan, Gareth J., Gregory, Walter M., Davies, Faith E., Bell, Sue E., Szubert, Alexander J., Brown, Julia M., Coy, Nuria N., Cook, Gordon, Russell, Nigel H., Rudin, Claudius, Roddie, Huw, Drayson, Mark T., Owen, Roger G., Ross, Fiona M., Jackson, Graham H., Child, J. Anthony, on behalf of the National Cancer Research Institute Haematological Oncology Clinical Studies Group · 2012 · Blood

Abstract

Thalidomide maintenance has the potential to modulate residual multiple myeloma (MM) after an initial response. This trial compared the effect of thalidomide maintenance and no maintenance on progression-free survival (PFS) and overall survival (OS) in MM patients. After intensive or nonintensive induction therapy, 820 newly diagnosed MM patients were randomized to open-label thalidomide maintenance until progression, or no maintenance. Interphase FISH (iFISH) analysis was performed at study entry. Median PFS was significantly longer with thalidomide maintenance (log-rank P < .001). Median OS was similar between regimens (log-rank P = .40). Patients with favorable iFISH showed improved PFS (P = .004) and a trend toward a late survival benefit. Patients with adverse iFISH receiving thalidomide showed no significant PFS benefit and worse OS (P = .009). Effective relapse therapy enhanced survival after progression, translating into a significant OS benefit. Meta-analysis of this and other studies show a significant late OS benefit (P < .001, 7-year difference hazard ratio = 12.3; 95% confidence interval, 5.5-19.0). Thalidomide maintenance significantly improves PFS and can be associated with improved OS. iFISH testing is important in assessing the clinical impact of maintenance therapy. Overview analysis demonstrated that thalidomide maintenance was associated with a significant late OS benefit. This trial was registered at www.isrctn.org as #ISRCTN68454111.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2011-06-357038

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 331

Metadata

Authors
Morgan, G. J., Gregory, W. M., Davies, F. E., Bell, S. E., Szubert, A. J., Brown, J. M., Coy, N. N., Cook, G., Russell, N. H., Rudin, C., Roddie, H., Drayson, M. T., Owen, R. G., Ross, F. M., Jackson, G. H., Child, J. A., & on behalf of the National Cancer Research Institute Haematological Oncology Clinical Studies Group
Venue
Blood
Published
2012-01-05
Volume
119
Issue
1
Pages
7-15
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2026448323
Cited by
331
References
24
FWCI
30.75
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. https://app.cochat.ai/papers/10.1182/blood-2011-06-357038
The paper
Morgan, G. J., Gregory, W. M., Davies, F. E., Bell, S. E., Szubert, A. J., Brown, J. M., Coy, N. N., Cook, G., Russell, N. H., Rudin, C., Roddie, H., Drayson, M. T., Owen, R. G., Ross, F. M., Jackson, G. H., Child, J. A., & on behalf of the National Cancer Research Institute Haematological Oncology Clinical Studies Group. (2012). The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. https://doi.org/10.1182/blood-2011-06-357038

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.